Literature DB >> 11134221

Why academic divisions of hematology/oncology are in trouble and some suggestions for resolution.

T J Smith1, J Girtman, J Riggins.   

Abstract

PURPOSE: Academic divisions of hematology/oncology seem to have difficulty recruiting and retaining excellent productive clinicians. A major reason for this is that salaries do not compete with the private sector for similar work.
METHODS: We reviewed divisional finances productivity, and experiences from faculty members leaving.
RESULTS: The academic salaries are approximately one third of practice because the chemotherapy concession has been given to the academic hospital. In addition, there may be substantial problems in under-billing, lack of attention to detail in billing, and poor collection practices.
CONCLUSION: Academic practice still has much to offer, including opportunities for research and multidisciplinary team management, although the differences may narrow over the coming years. Attention to detail in the billing, collection for work performed, and increasing academic salaries to levels nearer to private practice are necessary components of the solution to recruit and retain quality productive clinicians.

Mesh:

Year:  2001        PMID: 11134221     DOI: 10.1200/JCO.2001.19.1.260

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  3 in total

1.  Mission-focused, productivity-based model for sustainable support of academic hematology/oncology faculty and divisions.

Authors:  Randall F Holcombe; Krista J Hollinger
Journal:  J Oncol Pract       Date:  2010-02-19       Impact factor: 3.840

2.  The role of chemotherapy at the end of life: "when is enough, enough?".

Authors:  Sarah Elizabeth Harrington; Thomas J Smith
Journal:  JAMA       Date:  2008-06-11       Impact factor: 56.272

Review 3.  Treatment targeted at underlying disease versus palliative care in terminally ill patients: a systematic review.

Authors:  Tea Reljic; Ambuj Kumar; Farina A Klocksieben; Benjamin Djulbegovic
Journal:  BMJ Open       Date:  2017-01-06       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.